Evidence map›Paper›PMID 21660279›Full record

ArticlePathology research international2011

Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA.

Supriya D Mahajan, Ravikumar Aalinkeel, Jessica L Reynolds, Bindukumar Nair, Donald E Sykes, Wing-Cheung Law, Hong Ding, Earl J Bergey, Paras N Prasad, Stanley A Schwartz

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology research international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Supriya D MahajanDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, University at Buffalo, The State University of New York, 640 Ellicott Street, Room 444 Innovation Center, Buffalo, NY 14203, USA.
Ravikumar Aalinkeel
Jessica L Reynolds
Bindukumar Nair
Donald E Sykes
Wing-Cheung Law
Hong Ding
Earl J Bergey
Paras N Prasad
Stanley A Schwartz
University at Buffalo, State University of New York · US

Funding

Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic CancerR01CA119397 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PRASAD, PARAS N. · 2005 to 2009
$3.6M
Methamphetamine and HIV-1 Infection: Targeted Nanoparticles for Gene Silencing.K01DA024577 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2008 to 2012
$782k
Innovative Nanotherapy for Drug addiction.R21DA030108 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MAHAJAN, SUPRIYA DINKAR · 2010 to 2011
$390k
NCI NIH HHS R01 CA119397NIDA NIH HHS K01 DA024577NIDA NIH HHS R21 DA030108
6 · The paper itself

Abstract

HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality.

Identifiers

PMID21660279
PMCPMC3108557
OpenAlexW2164681755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.